Clinical trial
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903)
NCT04138212 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903)
- Lead sponsor
- Henan Cancer Hospital
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- October 22, 2019
- Completion date
- December 21, 2028
- Enrollment
- 456 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.